Search

Displaying results 2751 - 2760 of 10000 in total
  1. Drug

    Pegunigalsidase alfa

    go.drugbank.com/drugs/DB14992
    ApprovedInvestigational

    Pegunigalsidase alfa (PRX-102) is a recombinant form of human α-galactosidase-A indicated for long-term enzyme replacement therapy in patients with Fabry disease, a rare genetic disorder characterized … [A259352,L46342] Unlike other forms of recombinant alpha-galactosidase A, such as [agalsidase alfa] and [agalsidase beta], pegunigalsidase alfa uses a plant cell-based protein expression system, leading

  2. Drug

    REN-850

    go.drugbank.com/drugs/DB05912
    Experimental

    REN-850 is an oral drug for multiple sclerosis which is in Phase I of clinical trials.

  3. Drug

    Bendroflumethiazide

    go.drugbank.com/drugs/DB00436
    ApprovedInvestigational

    It has been used in the treatment of familial hyperkalemia, hypertension, edema, and urinary tract disorders. (From Martindale, The Extra Pharmacopoeia, 30th ed, p810)

    Mixtures: CORGARETIC (NADOLOL/ BENDROFLUMETIAZIDA) 80/5 MGProducts: Naturetin 5mg
  4. Drug

    Adiphenine

    go.drugbank.com/drugs/DB15795
    ApprovedWithdrawn

    Mixtures: SPASMO-PANALGINE 125 MG 10 SUPOZITUAR
  5. Drug

    Peanut oil

    go.drugbank.com/drugs/DB13964
    ApprovedWithdrawn

    The peanut oil represents about 45-52% of the kernel content and it is mainly formed from monounsaturated fat from which the major component is [DB04224]. … [A33169] Under the FDA, peanut oil is categorized as an approved inactive ingredient for its use in drug products.

  6. Drug

    MK-0773

    go.drugbank.com/drugs/DB16244
    Investigational

    MK-0773 is under investigation in clinical trial NCT00529659 (A Study of the Safety and Efficacy of MK-0773 in Women With Sarcopenia (Loss of Muscle Mass)(mk-0773-005)).

  7. Drug

    Moxetumomab pasudotox

    go.drugbank.com/drugs/DB12688
    ApprovedInvestigational

    [A38864] MxP appears as an improved form of BL22 by the mutation of the Fv region and the antibody phage-displayed. As well the residues SSY in the heavy chain are mutated to THW. … The predecessor of Moxetumab pasudotox (MxP), named BL22, was first created based on the antibody RFB4 which specifically binds to CD22.

  8. Drug

    Emapalumab

    go.drugbank.com/drugs/DB14724
    ApprovedInvestigational

    Emapalumab development was sponsored by NovImmune SA, further developed by Sobi and FDA approved on November 20, 2018. … [L4840] As well, emapalumab was given the status of PRIME by the EMA.[L4845]

  9. Drug

    MK-2748

    go.drugbank.com/drugs/DB15371
    Investigational

    MK-2748 is under investigation in clinical trial NCT01593735 (A Multiple Dose Study to Evaluate the Safety and Efficacy of MK-2748 in Hepatitis C-Infected Participants (MK-2748-002 AM1)).

  10. Drug

    L-aminocarnityl-succinyl-leucyl-argininal-diethylacetal

    go.drugbank.com/drugs/DB06124
    Experimental

    C-101 includes a carnitine carrier molecule and a leupeptin analogue, a known calpain inhibitor. Calpain is the primary protease that degrades skeletal muscle. … C-101, also called Myodur, is developed for the treatment of Duchenne’s muscular dystrophy (DMD) which is a morbid genetic disease that can lead to death in late adolescence due to accelerated skeletal